A detailed history of Gables Capital Management Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Gables Capital Management Inc. holds 3,663 shares of ABBV stock, worth $648,167. This represents 0.37% of its overall portfolio holdings.

Number of Shares
3,663
Previous 4,688 21.86%
Holding current value
$648,167
Previous $804,000 10.07%
% of portfolio
0.37%
Previous 0.43%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$163.84 - $199.33 $167,936 - $204,313
-1,025 Reduced 21.86%
3,663 $723,000
Q2 2024

Aug 07, 2024

BUY
$154.79 - $180.76 $30,958 - $36,152
200 Added 4.46%
4,688 $804,000
Q3 2023

Nov 02, 2023

BUY
$133.59 - $154.65 $9,351 - $10,825
70 Added 1.58%
4,488 $668,000
Q2 2023

Aug 02, 2023

BUY
$132.51 - $164.9 $26,502 - $32,980
200 Added 4.74%
4,418 $595,000
Q1 2023

May 03, 2023

BUY
$144.61 - $166.54 $6,652 - $7,660
46 Added 1.1%
4,218 $672,000
Q2 2021

Aug 03, 2021

SELL
$105.21 - $117.21 $468,710 - $522,170
-4,455 Reduced 51.64%
4,172 $470,000
Q2 2020

Jul 30, 2020

BUY
$73.37 - $98.18 $20,103 - $26,901
274 Added 3.28%
8,627 $847,000
Q1 2020

May 07, 2020

BUY
$64.5 - $97.79 $95,976 - $145,511
1,488 Added 21.68%
8,353 $637,000
Q4 2019

Feb 10, 2020

BUY
$72.13 - $90.25 $53,736 - $67,236
745 Added 12.17%
6,865 $607,000
Q3 2019

Oct 30, 2019

BUY
$62.98 - $75.72 $246,566 - $296,443
3,915 Added 177.55%
6,120 $463,000
Q1 2019

Apr 30, 2019

SELL
$77.14 - $90.79 $18,127 - $21,335
-235 Reduced 9.63%
2,205 $178,000
Q4 2018

Feb 08, 2019

SELL
$77.85 - $96.01 $32,307 - $39,844
-415 Reduced 14.54%
2,440 $225,000
Q1 2018

May 17, 2018

BUY
$92.01 - $123.21 $262,688 - $351,764
2,855 New
2,855 $270,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $313B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Gables Capital Management Inc. Portfolio

Follow Gables Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gables Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Gables Capital Management Inc. with notifications on news.